Zellerhaus is proud to announce that Skylit Medical has partnered with us to spearhead the development of their web asset for investors. We are excited about this new relationship, as Skylit Medical is on the forefront of developing some groundbreaking technology in the medical field.
Skylit Medical, based in San Diego, CA, is currently developing a solution for private phototherapy for people who suffer from eczema and psoriasis. In addition, the company will be developing technology that will allow for patient therapy to be monitored remotely by physicians.
Like many successful companies, Skylit was formed out of the necessity to introduce a home-based remedy for the physical ailment. Founder Martyn Gross found that most treatments were inconvenient, costly, and/or not scalable to the nearly half a billion people in the world who deal with eczema and psoriasis on a daily basis.
On partnering with Skylit Medical, founder Martyn Gross says “when it was determined that we needed to kick off this phase of our business, there was no question where to turn for this next step. Zellerhaus produces great work and we’re excited to be working on this asset with them.”
The site will be primarily geared towards investors, as well as have a secure investor’s backend. It will feature a modern, clean design, along with a parallax sliding home page design with inner page functionality.
Skylit Medical’s chairman is David F. Hale. Mr. Hale is the former CEO of Hybritech, Inc., and has served as chairman of Somaxon Pharmaceuticals (acquired by Pernix Therapeutics), Santarus, Inc. (acquired by Salix Pharmaceuticals), and SkinMedica, Inc. (acquired by Allergan). Skylit Medical is also a StartR Accelerator Company with headquarters at EvoNexus, a Commnexus Incubator.